Table 2. Univariate and multivariate survival analyses of patients with advanced gastric cancer according to various clinicopathological variables.

Variable	n	5-year	Univariate	Multivariate	HR	95% CI
		CSS (%)	P value	P value
Sex			0.084	0.398
Male	6658	6.9		0.398	1.020	0.974–1.067
Female	3696	6.1		ref	ref	ref
Age(year)			<0.001	<0.001
<75	7466	7.4		<0.001	0.731	0.697–0.768
≥75	2888	4.6		ref	ref	ref
Race			<0.001	0.002
White	7372	6.6		0.100	1.053	0.990–1.120
Black	1460	6.1		0.001	1.148	1.060–1.243
Other	1522	7.4		ref	ref	ref
Pathological grading			<0.001	<0.001
Grade I	188	7.8		0.051	0.845	0.713–1.001
Grade II	2013	9.6		<0.001	0.824	0.763–0.889
Grade III	6393	6.1		0.722	1.011	0.950–1.076
Grade IV	197	7.8		0.879	1.013	0.859–1.194
Unknown	1563	4.7		ref	ref	ref
Stage of T/Na			<0.001	<0.001
Stage I	2834	8.2		0.105	0.965	0.906–1.009
Stage II	2031	6.6		<0.001	0.834	0.787–0.884
Stage III	5489	6.1		ref	ref	ref
Histological type			<0.001	<0.001
Adenocarcinoma	7326	7.6		0.816	1.017	0.882–1.172
Signet ring cell	252	4.0		0.107	1.128	0.974–1.305
Mucinous	2776	8.3		ref	ref	ref
Treatment pattern			<0.001	<0.001
Surgery	2708	8.9		<0.001	0.603	0.570–0.637
RT	1355	5.7		<0.001	0.740	0.692–0.791
Surgery+RT	777	19.8		<0.001	0.366	0.334–0.401
No surgery/No RT	5514	3.2		ref	ref	ref

RT, radiation; CSS, cancer specific survival; HR, hazard ratio; CI, confidence interval; ref, reference.

^a Stage of T/N: Stage I include T1N0-1, T2N0; Stage II include T1N2-3, T2N1-2, T3N0-1, T4aN0; Stage III include T2N3, T3N2-3, T4aN1-3, T4bN0-3.